Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

With no cure for malignant pleural effusion, efforts are focused on symptomatic management. Historically, this symptomatic management was achieved with the instillation of a sclerosant agent into the pleural space to achieve pleurodesis. The development of the tunnelled indwelling pleural catheter and ambulatory pleural drainage changed the management of malignant pleural effusion, not solely by offering an alternative management pathway, but by challenging how health-care providers view success in a palliative condition. Furthermore, with additional treatment options available, increased imperative exists to better characterise patients to enable a personalised approach to their care. We have done a review of the scientific literature and clinical trial registries to provide an overview of the current and ground-breaking research published in the past 10 years.

Original publication

DOI

10.1016/s2213-2600(19)30373-x

Type

Journal article

Journal

The Lancet. Respiratory medicine

Publication Date

06/2020

Volume

8

Pages

609 - 618

Addresses

Academic Respiratory Unit, University of Bristol, Bristol, UK.

Keywords

Humans, Pleural Effusion, Malignant, Talc, Drainage, Pleurodesis, Single-Blind Method, Manometry, Floods, Thoracentesis